Current Crizotinib News and Events | Page 2

Current Crizotinib News and Events, Crizotinib News Articles.
Sort By: Most Relevant | Most Viewed
Page 2 of 3 | 120 Results
Validation of an IHC screening tool for ROS1 gene rearrangements
Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, a small-molecule tyrosine kinase inhibitor. (2016-05-11)

Study shows how TRK-fusion lung cancer escapes LOXO-101, offering new treatment strategies
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101 (2016-04-17)

A novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient
Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog receptor tyrosine kinase (KIT) that can potentially be targeted by KIT inhibitors. (2016-04-11)

Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive. (2016-04-08)

New drug may overcome treatment resistance in a high-risk children's cancer
Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma. The 'unparalleled' strength of an ALK inhibitor in their preclinical studies, say the researchers, justifies fast-tracking the drug into pediatric clinical trials this year. (2016-01-06)

Personalizing cancer therapies may combat resistance to targeted therapy drugs
Massachusetts General Hospital physicians report the case of a patients whose lung cancer was re-sensitized to crizotinib, a first-generation targeted therapy drug, by a mutation conferring resistance to a more selective, next-generation ALK inhibitor. (2015-12-23)

FDA continues recent trend of approval with new 2nd generation lung cancer treatment
The International Association for the Study of Lung Cancer is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients with the FDA's rapid progression of lung cancer drug approvals -- this time for alectinib for patients with advanced (metastatic) ALK-positive non-small cell lung cancer if their disease deteriorated after treatment with another therapy called crizotinib. Patients who could not tolerate treatment with crizotinib also qualify for use of alectinib. (2015-12-23)

Pancreatic cancer: CD44 protein induces metastases
Due to their rapid metastatic spread, pancreatic tumors are among the most aggressive types of cancer. Less than five percent of patients have a survival rate of five years. KIT researchers have now established the basis for new therapeutic approaches. In the Gastroenterology journal they report that in various pancreatic cancer mouse models CD44v6-specific peptides do not only inhibit the spread of tumor cells, but may even lead to the regression of already existing metastases. (2015-11-10)

Ceritinib in advanced lung cancer: No hint of added benefit
The drug manufacturer's dossier contained no study data suitable for an assessment for any of the two research questions. (2015-10-06)

Study defines criteria for MET-driven lung cancer suitable for crizotinib treatment
CU Cancer Center study presented at 16th World Conference on Lung Cancer defines criteria for MET-amplified cancer likely sensitive to treatment with crizotinib. (2015-09-08)

New tool uses 'drug spillover' to match cancer patients with treatments
An article in the journal Bioinformatics from researchers at the University of Colorado Cancer Center describes a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker predicts what genetics are truly driving the cancer in any population of cells and chooses the best 'kinase inhibitor' to silence these dangerous genetic causes of disease. (2015-07-28)

Promising trial of brigatinib shows all next-gen ALK inhibitors may not be created equal
Phase I/II clinical trial results reported at the American Society for Clinical Oncology Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer, with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. Progression-free survival in patients previously treated with crizotinib was 13.4 months. (2015-05-27)

Whose numbers determine cost-effectiveness of targeted anti-cancer therapies?
'Increasingly physicians are being presented with health economic analyses in mainstream medical journals as a means of potentially influencing their prescribing. However, it is only when you understand the multiple assumptions behind these calculations that you can see that they are by no means absolute truths,' says D. Ross Camidge, M.D., Ph.D., investigator at the University of Colorado Cancer Center. (2015-02-02)

Cancer-causing mutation discovered in 1982 finally target of clinical trials
A recent article in the journal Cancer Discovery describes clinical trials at the University of Colorado Cancer Center and elsewhere that match drugs to long-overlooked oncogene, TRK, offering targeted treatment options for cancers that harbor these gene abnormalities. (2014-12-29)

More evidence for impact of lung cancer targeted therapy from practice-changing trial
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy. (2014-12-04)

Study examines FDA influence on design of pivotal drug studies
An examination of the potential interaction between pharmaceutical companies and the US Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting, and when such meetings occurred, pharmaceutical companies did not comply with one-quarter of the recommendations made by the FDA regarding study design or primary outcome, according to a study in the Nov. 26 issue of JAMA. (2014-11-25)

Big data study identifies new potential target coating for drug-eluting stents
A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. Results of this study were published today in the Journal of Clinical Investigation. (2014-11-18)

'Big data' approach helps pinpoint possible new stent drug to prevent heart attacks
Stanford University School of Medicine researchers hunting for a better drug coating for coronary stents, the small mesh tubes used to prop open plaque-filled arteries, have pinpointed a cancer drug as a possible candidate. (2014-11-17)

Classification of gene mutations in a children's cancer may point to improved treatments
Oncology researchers studying gene mutations in the children's cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. (2014-11-10)

NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer
In this multi-center study of 50 patients with advanced non-small cell lung cancer testing positive for ROS1 gene rearrangement, the response rate was 72 percent, with 3 complete responses and 33 partial responses. Median progression-free survival was 19.2 months. (2014-09-30)

Crizotinib treatment effective against ROS1-positive lung cancer
Treatment with the targeted therapy drug crizotinib effectively halted the growth of lung tumors driven by rearrangements of the ROS1 gene in a small clinical trial. (2014-09-27)

ROS1 gene fusions are found in 2.4 percent of Asian patients with lung adenocarcinoma
ROS1 fusion genes were successfully detected independent of gender or smoking history in young East Asian patients with lung adenocarcinoma, a histological subgroup in non-small cell lung cancer, using multiplex reverse transcriptase-polymerase chain reaction and immunohistochemistry diagnostic tests. (2014-07-21)

ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
ASCO study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1 percent of patients testing positive. This and other work from Dr. Doebele's group forms the basis of a phase 1 clinical trial targeting NTRK1 mutations in advanced solid tumors (NCT02122913). (2014-05-31)

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease
A study presented at the American Society of Clinical Oncology Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). (2014-05-31)

Yale Cancer Center's tip sheet for the 50th Annual Meeting of ASCO May 30-June 3, 2014
The news items below are from oral presentations or poster sessions scheduled for the 50th annual ASCO conference. Yale Cancer Center will have experts available to speak with the media before or during ASCO. Abstracts cover immunotherapy for Melanoma and Bladder Cancer; PSMA; Breast Cancer Biomarkers; Cervical Cancer Screening; Non-Small Cell Lung Cancer; and Mental Health Comorbidities in VA Patients. (2014-05-23)

New general concept for the treatment of cancer
A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer. The concept is presented in the journal Nature and is based on inhibiting a specific enzyme called MTH1, which cancer cells, unlike normal cells, require for survival. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in cancer cells. (2014-04-02)

New drug successfully treats crizotinib-resistant, ALK-positive lung cancer
Now a new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug. (2014-03-26)

TGen study identifies gene fusion as likely cause of rare type of thyroid cancer
In a scientific first, the fusion of two genes, ALK and EML4, has been identified as the genetic driver in an aggressive type of thyroid cancer, according to a study by the Translational Genomics Research Institute. These groundbreaking findings are based on genetic sequencing of tumor cells from a 62-year-old patient with an aggressive tall cell variant of papillary thyroid cancer, according to the study published Tuesday, March 18, in the World Journal of Surgery. (2014-03-19)

Significant discrepancies between FISH and IHC results for ALK testing
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization and immunohistochemistry may enhance the detection of ALK-positive non-small cell lung cancer. (2014-02-24)

Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
Over the past decade, a great clinical focus has been directed at developing new and innovative therapies for advanced non-small cell lung cancer (NSCLC). An analysis of clinical trials evaluating these therapies demonstrates that the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate. However, biomarker- and receptor-targeted therapies were found to substantially increase clinical trial success. (2014-02-14)

'Weeding the garden' lets ALK+ lung cancer patients continue crizotinib
Patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. (2014-01-28)

Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients. (2013-12-17)

New crizotinib side-effect
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer appears to reduce kidney function when assessed by one of the most commonly used clinical methods. (2013-11-20)

CTCA doctor presents studies at World Conference on Lung Cancer in Australia
Glen J. Weiss, M.D., Director of Clinical Research, Cancer Treatment Centers of America® is presenting two key studies, including one today at the International Association for the Study of Lung Cancer's 15th World Conference on Lung Cancer being held in Sydney, Australia. (2013-10-31)

Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. (2013-10-20)

Study: Redefining the criteria for ALK positive lung cancer
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. (2013-09-10)

With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
If the science behind a drug shows it to be rationally targeted at a cancer-causing genetic mutation, and if early clinical trials show the drug is safe and happens to be especially effective, should the drug be held to the same time-consuming and expensive testing standards of traditional chemotherapies? Or is the clinical trials process a relic from the time of earlier, highly toxic therapies? (2013-08-08)

Some patients with treatment-resistant colorectal cancers may have a new option
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs. (2013-06-02)

RET rearrangement a new oncogene and potential target in lung cancer
In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: Rearrangement of the gene RET. (2013-06-02)

MGH-led studies shed new light on targeted lung cancer therapy
Research teams led by Massachusetts General Hospital Cancer Center investigators are publishing two important studies regarding use of the targeted cancer drug crizotinib for treatment of advanced lung cancer driven by specific genetic mutations. (2013-06-01)

Page 2 of 3 | 120 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to